Davita Inc vs VanEck Junior Gold Miners — how do they compare? Davita Inc trades at $178.56 (market cap $11.38B), while VanEck Junior Gold Miners trades at $119.61. Which is the better fit depends on your goals.
| DVA | GDXJ | |
|---|---|---|
Market Cap | $11.38B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $240.96 | $156.19 |
52-Week Low | $103.87 | $71.22 |
Enterprise Value | $24.10B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
GDXJ trades at $120.71, up 1.62% today, with a bullish technical trend from moving averages but overbought signals from RSI levels. The ETF faces mixed sentiment, with recent news highlighting institutional selling by Amundi and underperformance versus peers in 2026. Support lies near $116, with resistance at $121.
The outlook is cautious due to high RSI readings and bearish oscillators, suggesting potential near-term pullbacks. Risks include Federal Reserve policy impacts on gold prices and competitive pressures from larger miner ETFs. Institutional activity shows reduced positions, indicating tempered confidence.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →